ArticleSmall (Weinheim an der Bergstrasse, Germany)2020
Nanoparticle Drug Delivery Can Reduce the Hepatotoxicity of Therapeutic Cargo.
Article in Small (Weinheim an der Bergstrasse, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Precise and rapid release of X-ray activated autophagy inhibitors for radiotherapy sensitization of hypopharyngeal carcinoma.Materials today. Bio · 2026Article
- Emerging nanomedicine for liver diseases treatment.Journal of nanobiotechnology · 2025Review
- Tumor-specific surface marker-independent targeting of tumors through nanotechnology and bioorthogonal glycochemistry.The Journal of clinical investigation · 2025Article
- Glycyrrhizinate Monoammonium Cysteine-Loaded Lipid Nanoparticles Allow for Improved Acute Liver Injury Therapy.Pharmaceutics · 2025Article
- Rationally designed catalytic nanoplatform for enhanced chemoimmunotherapy via deploying endogenous plus exogenous copper and remodeling tumor microenvironment.Journal of nanobiotechnology · 2024Article
- Docetaxel-Loaded Methoxy poly(ethylene glycol)-poly (L-lactic Acid) Nanoparticles for Breast Cancer: Synthesis, Characterization, Method Validation, and Cytotoxicity.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Microglial targeted therapy relieves cognitive impairment caused byExploration (Beijing, China) · 2023Article
- Evaluation of drug carrier hepatotoxicity using primary cell culture models.Nanomedicine : nanotechnology, biology, and medicine · 2023Article
- Novel pH-Responsive Cubosome and Hexosome Lipid Nanocarriers of SN-38 Are Prospective for Cancer Therapy.Pharmaceutics · 2022Article
- Insulin-incubated palladium clusters promote recovery after brain injury.Journal of nanobiotechnology · 2022Article
- Article
- Polymeric nanoparticles-Promising carriers for cancer therapy.Frontiers in bioengineering and biotechnology · 2022Review
- Polyphenols Epigallocatechin Gallate and Resveratrol, and Polyphenol-Functionalized Nanoparticles Prevent Enterovirus Infection through Clustering and Stabilization of the Viruses.Pharmaceutics · 2021Article
- Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models.Acta biomaterialia · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 1 institution in 2 countries.
Funding
Abstract
Hepatotoxicity is a key concern in the clinical translation of nanotherapeutics because preclinical studies have consistently shown that nanotherapeutics accumulates extensively in the liver. However, clinical-stage nanotherapeutics have not shown increased hepatotoxicity. Factors that can contribute to the hepatotoxicity of nanotherapeutics beyond the intrinsic hepatotoxicity of nanoparticles (NPs) are poorly understood. Because of this knowledge gap, clinical translation efforts have avoided hepatotoxic molecules. By examining the hepatotoxicity of nanoformulations of known hepatotoxic compounds, it is demonstrated that nanotherapeutics are associated with lower hepatotoxicity than their small-molecule counterparts. It is also found that the reduced hepatotoxicity is related to the uptake of nanotherapeutics by macrophages in the liver. These findings can facilitate further development and clinical translation of nanotherapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.